SG11201401895WA - Administration of nedd8-activating enzyme inhibitor and hypomethylating agent - Google Patents
Administration of nedd8-activating enzyme inhibitor and hypomethylating agentInfo
- Publication number
- SG11201401895WA SG11201401895WA SG11201401895WA SG11201401895WA SG11201401895WA SG 11201401895W A SG11201401895W A SG 11201401895WA SG 11201401895W A SG11201401895W A SG 11201401895WA SG 11201401895W A SG11201401895W A SG 11201401895WA SG 11201401895W A SG11201401895W A SG 11201401895WA
- Authority
- SG
- Singapore
- Prior art keywords
- nedd8
- administration
- enzyme inhibitor
- activating enzyme
- hypomethylating agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161555049P | 2011-11-03 | 2011-11-03 | |
| PCT/US2012/063382 WO2013067396A2 (en) | 2011-11-03 | 2012-11-02 | Administration of nedd8-activating enzyme inhibitor and hypomethylating agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201401895WA true SG11201401895WA (en) | 2014-05-29 |
Family
ID=48193039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201401895WA SG11201401895WA (en) | 2011-11-03 | 2012-11-02 | Administration of nedd8-activating enzyme inhibitor and hypomethylating agent |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8980850B2 (en) |
| EP (1) | EP2773360B1 (en) |
| JP (2) | JP6231988B2 (en) |
| KR (1) | KR101987861B1 (en) |
| CN (1) | CN104245699B (en) |
| AU (1) | AU2012321106C1 (en) |
| BR (1) | BR112014010699B1 (en) |
| CA (1) | CA2854461C (en) |
| EA (1) | EA028380B1 (en) |
| ES (1) | ES2668272T3 (en) |
| GE (1) | GEP20196940B (en) |
| HK (1) | HK1201733A1 (en) |
| IL (1) | IL232353B (en) |
| MA (1) | MA35662B1 (en) |
| MX (1) | MX357835B (en) |
| MY (1) | MY176125A (en) |
| PL (1) | PL2773360T3 (en) |
| SG (1) | SG11201401895WA (en) |
| TN (1) | TN2014000194A1 (en) |
| TR (1) | TR201807342T4 (en) |
| UA (1) | UA114414C2 (en) |
| WO (1) | WO2013067396A2 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010132110A1 (en) | 2009-05-14 | 2010-11-18 | Millennium Pharmaceuticals, Inc. | Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate |
| BR112014004239A2 (en) * | 2011-08-24 | 2017-03-21 | Millennium Pharm Inc | nedd8 activating enzyme inhibitors |
| EP2764866A1 (en) * | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
| US20160074404A1 (en) | 2013-05-14 | 2016-03-17 | Millennium Pharmaceutcals, Inc. | Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents |
| KR20160035067A (en) * | 2013-07-26 | 2016-03-30 | 베링거 인겔하임 인터내셔날 게엠베하 | Volasertib in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome ii |
| WO2015154064A2 (en) | 2014-04-04 | 2015-10-08 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| CN103948590A (en) * | 2014-05-22 | 2014-07-30 | 中国药科大学 | NEDD8 (neural precursor cell-expressed developmentally downregulated 8)activating enzyme inhibitor and medical application thereof |
| EP3362070B1 (en) * | 2015-10-15 | 2021-01-27 | Celgene Corporation | Combination of a mutant isocitrate dehydrogenase 2 inhibitor with azacitidine and its use for treating acute myelogenous leukemia |
| WO2018218119A1 (en) * | 2017-05-25 | 2018-11-29 | The Board Of Trustees Of The Leland Stanford Junior University | Combination of low dose il-2 and an inhibitor of treg il-2r desensitization to treat autoimmune and allergic inflammatory diseases |
| JP2020534331A (en) * | 2017-09-21 | 2020-11-26 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ((1S, 2S, 4R) -4- {4-[(1S) -2,3-dihydro-1H-inden-1-ylamino] -7H-pyrrolo [2,3-D] pyrimidin-7-yl} -2-Hydroxycyclopentyl) Co-crystal form of methyl sulfamate, its formulation and use |
| MX2021005843A (en) * | 2018-11-20 | 2021-10-01 | Fulcrum Therapeutics Inc | Compositions and methods for increasing fetal hemoglobin and treating sickle cell disease. |
| TW202102495A (en) | 2019-03-15 | 2021-01-16 | 美商弗爾康醫療公司 | Macrocyclic azolopyridine derivatives as eed and prc2 modulators |
| WO2023025668A1 (en) | 2021-08-25 | 2023-03-02 | Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune | Methods for the generation of stem cell memory t cells for adoptive t cell therapy |
| WO2023242235A1 (en) * | 2022-06-14 | 2023-12-21 | Scandion Oncology A/S | Abcg2 inhibitor and nae inhibitor for the treatment of cancer |
| CN115007323B (en) * | 2022-06-17 | 2024-01-23 | 中南大学 | Method for inhibiting pyrite floatation in minerals |
| WO2024012414A1 (en) * | 2022-07-11 | 2024-01-18 | Westlake University | Use of a fbxo42 specific inhibitor in treating notch signaling-dependent disease |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6887855B2 (en) | 2003-03-17 | 2005-05-03 | Pharmion Corporation | Forms of 5-azacytidine |
| US6943249B2 (en) | 2003-03-17 | 2005-09-13 | Ash Stevens, Inc. | Methods for isolating crystalline Form I of 5-azacytidine |
| US20060063735A1 (en) | 2004-09-17 | 2006-03-23 | Supergen, Inc. | Salts of 5-azacytidine |
| US20060128654A1 (en) | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of cytidine analogs and derivatives |
| JP5048520B2 (en) | 2005-02-04 | 2012-10-17 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | Inhibitor of E1 activating enzyme |
| EP2402334B1 (en) | 2006-02-02 | 2016-06-29 | Millennium Pharmaceuticals, Inc. | Inhibitors of E1 Activating Enzymes |
| MY157177A (en) * | 2006-08-08 | 2016-05-13 | Millennium Pharm Inc | Heteroaryl compounds useful as inhibitors of e1 activating enzymes |
| WO2008028193A2 (en) | 2006-09-01 | 2008-03-06 | Pharmion Corporation | Colon-targeted oral formulations of cytidine analogs |
| WO2009058394A1 (en) | 2007-11-01 | 2009-05-07 | Celgene Corporation | Cytidine analogs for treatment of myelodysplastic syndromes |
| US20110021517A1 (en) * | 2008-02-26 | 2011-01-27 | Nerviano Medical Sciences S.R.L. | Antitumor combination comprising a morpholinyl anthracycline derivative and demethylating agents |
| PL2299984T3 (en) | 2008-05-15 | 2019-07-31 | Celgene Corporation | Oral formulations of cytidine analogs and methods of use thereof |
| NZ589719A (en) * | 2008-06-09 | 2012-08-31 | Cyclacel Ltd | Combinations of sapacitabine or cndac with dna methyltransferase inhibitors such as decitabine and procaine |
| MX2011009989A (en) * | 2009-03-23 | 2011-10-14 | Ambit Biosciences Corp | Methods of treatment using combination therapy. |
| WO2010132110A1 (en) | 2009-05-14 | 2010-11-18 | Millennium Pharmaceuticals, Inc. | Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate |
| JP2014503597A (en) | 2011-01-31 | 2014-02-13 | セルジーン コーポレイション | Pharmaceutical composition of cytidine analogue and method of use thereof |
| US9125884B2 (en) | 2011-11-01 | 2015-09-08 | Celgene Corporation | Methods for treating cancers using oral formulations of cytidine analogs |
-
2012
- 2012-11-02 CA CA2854461A patent/CA2854461C/en active Active
- 2012-11-02 MY MYPI2014001239A patent/MY176125A/en unknown
- 2012-11-02 GE GEAP201213483A patent/GEP20196940B/en unknown
- 2012-11-02 US US13/667,641 patent/US8980850B2/en active Active
- 2012-11-02 WO PCT/US2012/063382 patent/WO2013067396A2/en active Application Filing
- 2012-11-02 CN CN201280062112.9A patent/CN104245699B/en active Active
- 2012-11-02 EA EA201400539A patent/EA028380B1/en not_active IP Right Cessation
- 2012-11-02 BR BR112014010699-1A patent/BR112014010699B1/en not_active IP Right Cessation
- 2012-11-02 KR KR1020147014236A patent/KR101987861B1/en active IP Right Grant
- 2012-11-02 SG SG11201401895WA patent/SG11201401895WA/en unknown
- 2012-11-02 AU AU2012321106A patent/AU2012321106C1/en not_active Ceased
- 2012-11-02 JP JP2014540146A patent/JP6231988B2/en active Active
- 2012-11-02 TR TR2018/07342T patent/TR201807342T4/en unknown
- 2012-11-02 ES ES12844799.2T patent/ES2668272T3/en active Active
- 2012-11-02 PL PL12844799T patent/PL2773360T3/en unknown
- 2012-11-02 MX MX2014005323A patent/MX357835B/en active IP Right Grant
- 2012-11-02 UA UAA201405842A patent/UA114414C2/en unknown
- 2012-11-02 EP EP12844799.2A patent/EP2773360B1/en active Active
-
2014
- 2014-04-29 IL IL232353A patent/IL232353B/en active IP Right Grant
- 2014-04-30 TN TNP2014000194A patent/TN2014000194A1/en unknown
- 2014-05-26 MA MA37066A patent/MA35662B1/en unknown
-
2015
- 2015-01-23 US US14/603,717 patent/US20150366886A1/en not_active Abandoned
- 2015-03-06 HK HK15102294.2A patent/HK1201733A1/en unknown
-
2017
- 2017-10-20 JP JP2017203560A patent/JP2018009035A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1201733A1 (en) | Administration of nedd8-activating enzyme inhibitor and hypomethylating agent nedd8- | |
| HRP20180953T1 (en) | Substituted 3-haloallylamine inhibitors of ssao and uses thereof | |
| HK1246674A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| HK1199726A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3- | |
| HK1203853A1 (en) | Inhibitors of arginase and their therapeutic applications | |
| EP2678018A4 (en) | Combination of kanase inhibitors and uses thereof | |
| HK1202112A1 (en) | Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase | |
| HK1202244A1 (en) | Prebiotic formulations and methods of use | |
| EP2721019A4 (en) | Therapeutically active compositions and their methods of use | |
| HK1198619A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3- | |
| EP2790709A4 (en) | Hemostatic agents and methods of use | |
| IL232115A0 (en) | Pharmaceutical compositions comprising dgla and /or 15-hetre and methods of use thereof | |
| EP2635287A4 (en) | Administration of nedd8-activating enzyme inhibitor | |
| HK1201066A1 (en) | Pyranopyridone inhibitors of tankyrase | |
| EP2688901A4 (en) | INHIBITORS OF 17ß-HSD1, 17ß-HSD3 AND 17ß-HSD10 |